Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, was recently featured in an exclusive audio interview with NetworkNewsWire. During the interview, POAI CEO Carl Schwartz noted recent milestones, outlined strategic goals and provided key updates on the company’s four impressive … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shines Spotlight on Innovative Media in Exclusive Interview”
Precision medicine is emerging approach to disease prevention, treatment that incorporates individual’s distinctive characteristics. New approach allows doctors, researchers to predict more accurately which treatments may work better. Helomics’ database, largest of its kind, is comprised of ovarian, head and neck, colon and pancreas tumors. Science has discovered that thumbprints and DNA aren’t the only … Continue reading “Predictive Oncology (NASDAQ: POAI) Leverages Precision Medicine Expertise to Support Oncologists, Improve Patient Outcomes”
Precision oncology leverages the profile of genetic mutations in patients for the purpose of delivering precision drug-based cancer therapy Precision oncology industry forecast to be worth 99.72 billion by 2027 according to recent report POAI applies AI to proprietary data trove, aiding oncologists in personalizing cancer therapies in addition to collaborating with pharmaceutical companies for … Continue reading “Using AI-Powered Models and Drug-Response Data, Predictive Oncology (NASDAQ: POAI) Holds Strong Position in Burgeoning Precision Oncology Industry”
Financial numbers show revenues stay level, gross margins up and operations expenses down. Company continues focus on primary mission of applying artificial intelligence to precision medicine, drug discovery. POAI subsidiaries all showing progress, growth in key areas. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug … Continue reading “Predictive Oncology (NASDAQ: POAI) Releases Third-Quarter 2020 Business Update, Financial Report”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Shareholder Letter Regarding Special Meeting”
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Through its subsidiary Soluble Biotech, the company delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. A recent article discussing this reads, “HSC Technology is … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Solution Shaves Time, Money to Optimize Therapeutic Formulations”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its virtual Special Meeting of Stockholders, which was scheduled for Dec. 1, 2020, was held but no business was conducted because a full quorum was not in attendance. The meeting has been rescheduled for … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Reschedules Special Stockholder Meeting, Urges Stockholder Voting”
Closed design of Streamway(R) System provides safety from potential hazards of drips and spills during endoscopy, radiology, cystoscopy, urology procedures The Streamway(R) System reduces costs, minimizes environmental impact of 50 million potentially disease-infected canisters disposed into landfills POAI’s Skyline Medical sells 8 Streamway(R) Systems to large university hospital in Virginia, 15 sold halfway into Q3 … Continue reading “Predictive Oncology’s (NASDAQ: POAI) Skyline Medical Sells 15 Streamway(R) Systems in Q3 2020 as COVID-era Drives Need for Sanitation Systems”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its financial results and provided business updates for the quarter ended Sept. 30, 2020. The report included a note that revenues of $0.5 million were level with the third quarter of last year, primarily … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Q3 Numbers, Company Updates”
CEO expects results that will “build the stock and raise the stock price” POAI focused on positioning TumorGenesis kits to manufacturers Helomics has largest database of its kind in the world, brings cutting-edge technology to cancer research During a recent NetworkNewsWire exclusive audio interview, Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz noted recent company milestones … Continue reading “Predictive Oncology (NASDAQ: POAI) CEO Discusses Subsidiaries’ Proprietary Tech, Innovative Media”
